To design a unique format with optimal T-cell-redirecting activity toward either Her2 or VEGFR2 on cancer cells, we modified the recombination approach using various linker designs for the site-specific fusion of Her2 (2Rs15)- or VEGFR2 (3VGR19)- specific nanobodies to various sites of the CD3 Fab (SP34). This evidence concerns the gene KDR and cancer.